ISSUE 10/2025

BDMAI BULLETIN

From the Desk of President

Dear Friends,

I am truly delighted to connect with you all through this edition of the BDMAI Bulletin.

At the outset, I extend my heartfelt gratitude for entrusting me with the responsibility of serving as the National President of this esteemed Association. It is indeed a great honour to follow in the footsteps of my distinguished predecessors — stalwarts of our industry — who have worked tirelessly to unify and uplift the members of BDMAI.

While I recognize the formidable challenge of living up to the wisdom, vision, and dedication of these great leaders, I assure you that I will strive with utmost sincerity and commitment to uphold the values and legacy they have established.

During my tenure, one of my key priorities will be to actively engage with local associations of bulk drug manufacturers and other stakeholders across various States. My aim is to bring all such bodies under a common platform, thereby strengthening our collective voice in addressing industry-related challenges, advocating policy reforms, and liaising with government agencies more effectively.

This mission can only be realized with your continued support and active participation in the Association's initiatives. Together, I am confident that we can take our industry to greater heights.

With warm Regards

Ch. A P Rameswara Rao
National President

In this Bulletin you can expect

Global Pharma News

New Drug Developments, Investments, Drug Approvals, JVs

BDMAI Activities

Representations
Meetings
Notifications

Technical & Commercial Articles

Analysis of Import & Export of APIs

Global Pharma News

Investments

Eli Lilly to Build $5 Billion Manufacturing Plant in Virginia, Expanding US Biopharma Capacity

Eli Lilly's $5 billion Virginia plant is part of a $50 billion US expansion, focusing on antibody-drug conjugates and bioconjugate innovation. The facility will create 650 high-paying jobs and 1,800 construction jobs, boosting Virginia's economy and pharmaceutical supply chain.

Pharmaceutical Commerce 17.9.2025

GSK Commits $30B to Strengthen US Biopharma R&D and Manufacturing Capacity

GSK commits $30 billion to US R&D and pharma supply chain, including $1.2 billion for advanced production and AI-driven facilities. A new biologics flex factory in Pennsylvania will focus on respiratory and cancer treatments, enhancing US-based production. Eli Lilly's $5 billion Virginia plant highlights the trend of reshoring pharmaceutical manufacturing to the US. President Trump's drug pricing executive order and tariffs create industry pressure, with legal challenges to tariff enforcement ongoing

Pharmaceutical Commerce 18.9.2025

Lilly to site next US manufacturing facility in Texas

The new $6.5 billion Houston site will manufacture active pharmaceutical ingredients (APIs) in support of the company's pipeline of small molecule medicines. Lilly has chosen Generation Park in Houston, Texas to site the second of its four new US manufacturing facilities. The first plant in Virginia was announced last week, with the remaining two expected by the end of the year. The new $6.5 billion facility in Texas will manufacture next-generation small molecule synthetic medicines across Lilly's therapeutic areas including cardiometabolic, oncology and neuroscience

European Pharmaceutical Review 25.9.2925

Joint Ventures / Acquisitions:

Novartis builds on Monte Rosa collaboration with $5.7 billion deal

Expanding its collaboration with the US biotech will add novel molecular glue degrader-based medicines to the pharma company's pipeline The deal potentially puts the Boston-based biotech inline for a $5.7 billion pay out from developmental, regulatory and commercial milestones payments across various research programmes. As part of the agreement Monte Rosa will also receive $120 million upfront and is eligible for tiered royalties

on global net sales. The firm will use its AI/ML-enabled product engine for development of the degraders, which will then in turn be further development and commercialised by Novartis.

European Pharmaceutical review 17.9.2025

Celltrion to Acquire Eli Lilly's $330M Production Plant

Celltrion, a South Korean pharmaceutical company, revealed via a regulatory filing that its US subsidiary (Celltrion USA) is purchasing Eli Lilly's biopharma manufacturing facility in Branchburg, NJ for $330 million.[1,2] It was originally owned by Imclone Systems LLC, who was acquired by Lilly in 2008. The move—confirmed by *Reuters* and *The Korea Times*—is expected to be in response to the forthcoming pharma tariffs that'll be impacting the United States.

Pharmaceutical Commerce 23.9.2025

MSD pays up to nearly $600m for Evaxion's mystery vaccine candidate

Evaxion's preclinical asset targets an unknown infectious disease in which there are no other vaccines available \. Merck & Co (MSD) has taken the first of two possible plunges in its ongoing collaboration with Evaxion, gaining the rights to a mystery infectious disease vaccine candidate. The US big pharma decided to option a licensing deal for AI-discovered vaccine EVX-B3, which will see Evaxion in line for nearly $600m. The deal is part of a previous agreement between the two companies from September 2024 that gave MSD the option to exclusively license EVX-B3, as well as potential gonorrhoea vaccine EVX-B2.

Pharmaceutical technologies 25.9.205

Takeda Partners with VELA to Launch Wind-Powered Medicine Transport Across the Atlantic

Takeda and VELA Transport's partnership introduces wind-powered trimarans for transatlantic shipping, significantly reducing greenhouse gas emissions. The trimarans' design emphasizes circularity, using recyclable aluminum and renewable energy-powered refrigeration to maintain product quality. Takeda aims for net-zero greenhouse gas emissions by 2040, with this collaboration addressing Scope 3 emissions in the pharmaceutical supply chain. VELA plans to operate five trimarans by 2028, offering faster delivery times than traditional containerized sea cargo shipping.

Pharmaceutical Commerce 29.9.2025

Genmab makes $8bn acquisition to boost late-stage antibody therapy pipeline

The deal will support the biotech in its plans to advance bispecific antibody petosemtamab in multiple oncology indications. The proposed deal aligns with Genmab's focus on antibody therapy development and commercialisation in oncology and is anticipated to support the company in shifting to a wholly owned model, strengthening its revenue base and supporting its growth into 2030. Petosemtamab is an EGFRxLGR5 bispecific antibody with potential as a first- and best-in-class drug in both head and neck cancer, according to Merus. Phase II data presented at the American Society for Clinical Oncology (ASCO) 2025 Annual Meeting showed both "substantially higher" overall response rate and median progression free survival compared to standard of care.

European Pharmaceutical Review 29.9.2025

New Drug Developments:

EASD 2025: Zimislecel infusion advances insulin independence in T1D

From a pharmaceutical strategy perspective, zimislecel could anchor a premium, disease-modifying segment in high-risk T1D. At the 2025 European Association for the Study of Diabetes (EASD) meeting in Vienna, investigators reported one-year outcomes from FORWARD, a pivotal study of zimislecel (VX-880), an allogeneic, stem cell-derived islet therapy. Among 12 adults with Type 1 Diabetes (T1D) who received a single full-dose infusion, mean HbA1c fell from 7.8% to 6.0%. In addition, 83% achieved insulin independence and severe hypoglycemic events (SHEs) were eliminated

Pharmaceutical Technologies 17.9.2025

Bimekizumab shows sustained three-year efficacy in hidradenitis suppurativa

Data from trials highlight long-term disease control and quality of life improvements. UCB has announced new three-year data for BIMZELX (bimekizumab) in moderate to severe hidradenitis suppurativa (HS), showing sustained disease control and symptom resolution across the most stringent clinical endpoints. Bimekizumab is the first approved treatment to selectively inhibit interleukin 17A and 17F. It continues to be well tolerated, with no new safety signals observed over three years.

Pharma Times 17.9.2025

Nxera and Cancer Research UK begin phase 2a trial of HTL0039732

First patient dosed in study of novel EP4 antagonist for advanced solid tumoursxe. Nexra Pharma and Cancer Research UK have announced the first patient has been dosed in a phase 2a trial of HTL0039732, an investigational oral EP4 antagonist being developed to treat advanced solid tumours in combination with immunotherapy. The trial follows successful completion of phase 1, which identified a safe and well-tolerated dose of HTL0039732 with checkpoint inhibitor atezolizumab. The drug showed good target engagement of EP4 without significantly affecting EP2.

Pharma Times 17.9.2025

Novo Nordisk: Ozempic Lowers Heart Attack, Stroke, and Death Risk by 23% vs. Dulaglutide in Real-World Study

Novo Nordisk announced new findings from the REACH real-world study demonstrating that Ozempic (once-weekly injectable semaglutide) reduced the risk of major adverse cardiovascular events—such as heart attack, stroke, and death—by 23% compared to dulaglutide. The study analyzed data from nearly 60,000 U.S. Medicare patients aged 66 and older living with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD), a condition that increases the risk of cardiovascular complications.

Pharma Journalist 19.9.2025

Drug Approvals:

FDA ends HAE drought with record year of approvals

FDA approvals in HAE were sparse before this year, with only one each in 2017, 2018, and 2020. After four years of inactivity, the US Food and Drug Administration (FDA) approved three novel products for hereditary angiooedema (HAE) in 2025. This bumper year increased the total number of marketed innovator drugs within the US to 11, introducing new mechanisms and modalities which broaden the treatment strategies available to patients. HAE is a potentially life-threatening inherited disease. This disorder is characterised by recurrent and severe episodes of swelling in various parts of the body, including the hands, feet, genitals, stomach, and face or throat, which can prove fatal. This is a rare condition, which is estimated to affect only 7,000 people in the US, approximately.

Globaldata Healthcare 18.9.2025

European Commission approves ROMVIMZA for TGCT treatment

Vimseltinib becomes first authorised therapy for tenosynovial giant cell tumour in the EU. The European Commission has approved ROMVIMZA (vimseltinib) for adult patients with symptomatic tenosynovial giant cell tumour (TGCT) in the EU. The decision marks the first marketing authorisation for a TGCT therapy in Europe. Vimseltinib is indicated for patients with physical function deterioration where surgery is not viable or would cause unacceptable harm. The approval was announced by Ono Pharmaceutical and Deciphera, who jointly developed the treatment.

Pharma Times 18.9.2025

Lilly wins European Alzheimer's approval for Kisunla after regulatory setbacks

The anti-amyloid monoclonal antibody is part of the class of medicines representing the first disease-modifying therapies for the neurodegenerative disease. In March European Medicines Agency (EMA) advisors refused to back its approval, believing its benefits were not enough to outweigh the risk of potentially fatal events due to amyloid-related imaging abnormalities (ARIA), involving swelling and potential bleeding in the brain. After re-examining the drug the EMA's committee for Medicinal Products for Human Use (CHMP) recommended Kisunla for approval, but only for a subset of the patient population. Consequently, the monoclonal antibody is now indicated for adults with mild cognitive impairment and individuals with mild dementia stages of Alzheimer's, but only for those that do not have a copy of the ApoE4 gene, a certain form of the gene for the protein apolipoprotein E, or people who have only one copy of the gene.

European Pharmaceutical Review 27.9.2025

Biostar Pharma's Utidelone Receives Third Orphan Drug Designation from FDA for Pancreatic Cancer

Biostar Pharma, the U.S. subsidiary of Beijing Biostar Biopharmaceutical, announced that its core drug candidate, Utidelone, has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic cancer. This marks

the third ODD for Utidelone, following earlier designations for breast cancer brain metastases and gastric cancer.

Pharma Journalist 26.9.2025

J&J's Tremfya secures two paediatric psoriasis approvals from FDA

The US FDA approvals make the drug the first IL-23 inhibitor to be licensed for two common skin conditions. The subcutaneous injection monoclonal antibody is now indicated for children six years old and over who weigh at least 40kg with moderate to severe plaque psoriasis (PsO), and are candidates for systemic therapy or phototherapy, or who have active psoriatic arthritis (PsA).

European Pharmaceutical Review 30.9.2025

REPRESENTTIONS:

BDMAI has made the following Representations to various Government departments, based on the input/ requests from the members:

DCA, Telangana

Based on the feedback received from the members in an internal meeting, a representation dated 10th September 2025 was made to Sri Shahnawaz Qasim IPS O/o The Director General, Drugs Control Bhavan, Drugs Control Administration Hyderabad with a Request for allowing off-line application of WHO GMP (CoPPs) also till the doubts and clarification were addressed. Please click here to see the representation.

APPCB

BDMAI represented to APPCB requesting them to allow the industries to avail the COD limit of 500 mg / liter as allowed in the notification issued by MoEF & CC. Please click here to see the representation.

Circulars:

Following circulars have been sent to the members during the Sep – Oct 2025

Sl. No.	Date of Issue	Subject
1	7.10.2025	Pharma Bulk Drug Manufacturing Summit – 15th October 2025 at Hotel Radisson Blu, Banjara Hills, Hyderabad
2	29.9.2025	**Recruitment Drive for fresh B.Sc./M.Sc./ B.Tech. / M. Tech/ B. Pharm / M Pharm ITI/Diploma candidates at Palamuru University on 11th October 2025**
3	22.9.2025	**Minimum Import Price on Potassium Clavulanate and its intermediates**
4	26.9.2025	**New Team of Office Bearers of BDMAI**
5	16.9.2025	**Inputs required – Use of Perfluorooctyl Iodide for production of Perfluorooctyl Bromide**
6	11.9.2025	**Webinar organized by DGTS-AEO Programme & MOOWR Scheme**

Events:

Annual General Meeting of Association:

BDMAI celebrated its 34th Annual meeting on 18th September 2025. On the eve of this, apart from carrying the statutory requirements, BDMAI organized 'Fireside Chat' with Sri G V Prasad, Vice Chairman & Managing Director of Dr. Reddy's Laboratories Ltd. Sri Jayant Tagore, Managing Director, Synthokem Laboratories & Former President of BDMAI, Dr. P V Appaji, Hon. Advisor of BDMAI chatted with Sri G V

Prasad, who shared his thoughts, experiences on various topics, including impact of recent tariffs by US, heavy dependence of China for imports, role of Green Chemistry, AI & Digitalization in API manufacturing, Government initiatives etc. The discussion was very inspiring and received a standing ovation from the audience.

Recruitment Drive

In association with Telangana State Council for Higher Education and Palamuru Univeristy, BDMAI is organizing a mega Recruitment Drive

of Fresh Candidates on 11th October 2025 and University Campus of Palamuru, Mahbubnagar. .Ten of our member companies are participating in the Drive.

Pharma Bulk Drug Manufacturing Summit:

BDMAI is actively supporting an one-day submit on Pharma Bulk Drug Manufacturing which will be held on 15th October 2025 at Hyderabad.

Corrosion Risk Management and Process Safety in Pharma and Chemical Industries:

BDMAI is actively supporting in the above titled one-day seminar which is also be held on 15th October 2025. Interested members may register by using the link https://www.indianchemicalnews.com/alleima-2025/

Aragen Life Sciences is proud to announce that it has been named one of **Asia-Pacific's Climate Leaders 2025** by the Financial Times in the Healthcare sector. This recognition underscores Aragen's sustained commitment to reducing its environmental footprint and advancing responsible growth.

The annual list, developed with Statista, features companies that achieved significant reductions in Scope 1 and 2 greenhouse gas emissions intensity between 2018 and 2023 while showing strong transparency and engagement on sustainability. Key factors that contributed to Aragen's inclusion include:

- Collaboration with global initiatives such as CDP and the Science Based Targets initiative (SBTi)
- Disclosure of Scope 3 emissions and improved data coverage across the value chain
- Robust methodological checks and third-party scrutiny of data

This recognition places Aragen among the region's leading climate-focused companies from Japan, Taiwan, and Australia, and reflects our commitment to a resilient, low-carbon future. It reaffirms our pledge to embed sustainability across our operations and work with stakeholders to drive a greener healthcare ecosystem.

Link to website: https://www.ft.com/climate-leaders-asia-pacific-2025

Pressure Protection and Safety in Pharmaceutical Manufacturing Facilities

World Pharma Today 25.9.2025

The pharmaceutical manufacturing industry operates under some of the most stringent safety requirements of any industrial sector, with pressure protection pharma manufacturing systems serving as critical safeguards for personnel, equipment, and the surrounding community. The complexity of modern pharmaceutical processes, combined with the potentially hazardous nature of many chemical compounds and the precision required for product quality, demands comprehensive safety systems that address every aspect of pressure-related risks throughout the manufacturing facility.

The evolution of pressure protection systems in pharmaceutical manufacturing reflects decades of technological advancement, regulatory development, and painful lessons learned from industrial incidents. Today's approaches integrate multiple layers of protection, sophisticated monitoring systems, and advanced control technologies to create comprehensive safety frameworks that protect against both routine operational hazards and catastrophic failure scenarios.

Fundamental Principles of Pressure Safety



Hierarchy of Pressure Protection and Safety Controls in Pharmaceutical Manufacturing

The foundation of effective pressure protection rests upon comprehensive understanding of the pressure dynamics inherent in pharmaceutical manufacturing processes. These processes typically involve complex interactions between multiple pressure systems, including reaction vessels operating under positive pressure, vacuum systems for distillation and drying operations, and compressed air systems for instrumentation and material handling.

Pharma safety systems must address both static pressure conditions, where equipment operates at steady-state pressures, and dynamic pressure scenarios, where pressure changes rapidly due to process upsets, equipment failures, or operator interventions. The design of effective pressure protection requires detailed analysis of all potential pressure sources, failure modes, and interaction effects that could lead to hazardous conditions.

Process safety management principles provide the systematic framework for identifying, evaluating, and controlling pressure-related hazards throughout pharmaceutical facilities. These principles emphasize the importance of comprehensive hazard analysis, robust engineering controls, effective administrative procedures, and continuous monitoring and improvement of safety performance.

The hierarchy of controls principle guides the selection and implementation of pressure protection measures, prioritizing engineering controls that eliminate or reduce hazards at their source over administrative controls and personal protective equipment that rely on human behavior for effectiveness. This approach ensures that the most reliable and effective protection measures receive priority in system design and resource allocation.

Engineering Controls and Hardware Protection

The primary line of defense against pressure-related hazards consists of engineering controls integrated directly into process equipment and facility design. These systems provide automatic protection that operates independently of human intervention, offering the highest level of reliability and effectiveness for critical safety applications.

Pressure control pharma systems incorporate sophisticated instrumentation and control technologies that continuously monitor pressure conditions and automatically implement corrective actions when pressure deviations are detected. Advanced pressure transmitters provide highly accurate, real-time pressure measurements with diagnostic capabilities that can detect potential instrument failures before they compromise safety systems.

Relief valve systems represent the most fundamental pressure protection technology, providing automatic pressure relief when system pressures exceed safe operating limits. Modern relief valves incorporate advanced materials, precision manufacturing, and sophisticated design features that ensure reliable operation under diverse operating conditions. The selection and sizing of relief valve systems requires detailed analysis of process conditions, potential overpressure scenarios, and discharge system requirements.

Rupture disc systems provide secondary pressure protection for applications where the consequences of overpressure could be catastrophic. These devices offer several advantages over relief valves, including absolute leak-tight performance under normal operating conditions, rapid opening characteristics, and resistance to corrosion and fouling. Advanced rupture disc designs incorporate sophisticated materials and manufacturing techniques that provide precise opening pressures and predictable failure characteristics.

Vacuum protection systems address the unique hazards associated with vacuum operations, which are common in pharmaceutical manufacturing for distillation, drying, and crystallization processes. These systems must protect against both excessive vacuum conditions that could cause equipment collapse and sudden vacuum loss that could create hazardous pressure waves or allow atmospheric contamination of process materials.

Containment and Isolation Technologies

Containment systems pharma applications have evolved significantly to address the unique challenges of handling highly potent active pharmaceutical ingredients and other hazardous materials. These systems provide multiple barriers between potentially hazardous materials and facility personnel, creating controlled environments that enable safe handling while maintaining product quality and process efficiency.

Isolator technology represents the most advanced approach to containment, creating completely enclosed working environments that physically separate hazardous materials from facility personnel. Modern isolator systems incorporate sophisticated pressure control systems that maintain appropriate pressure differentials, advanced filtration systems that prevent contamination, and comprehensive monitoring systems that ensure containment integrity.

Glove box systems provide an intermediate level of containment for applications where complete isolation is not required but enhanced protection is necessary. These systems enable direct manipulation of materials while maintaining physical separation between operators and potentially hazardous substances. Advanced glove box designs incorporate sophisticated ventilation systems, pressure monitoring, and emergency procedures that ensure operator safety even under upset conditions.

Negative pressure rooms and areas provide facility-level containment for operations involving hazardous materials. These systems maintain lower pressure in controlled areas compared to adjacent spaces, ensuring that any air leakage flows inward rather than allowing contaminated air to escape to uncontrolled areas. The design of effective negative pressure systems requires careful consideration of air balance, filtration requirements, and emergency procedures.

Barrier systems create physical separation between operators and hazardous processes while allowing necessary access for process monitoring and control. These systems range from simple physical barriers to sophisticated restricted access barrier systems that provide high levels of protection while maintaining operational flexibility.

Monitoring and Detection Systems

Comprehensive monitoring systems provide continuous surveillance of pressure conditions throughout pharmaceutical facilities, enabling early detection of potential problems and rapid response to emergency situations. These systems integrate multiple sensor technologies, advanced data analysis capabilities, and sophisticated alarm management to ensure that safety-critical information reaches appropriate personnel quickly and reliably.

Real-time pressure monitoring systems utilize advanced sensor technologies to provide continuous measurement of pressure conditions throughout the facility. These sensors must operate reliably in the challenging environment of pharmaceutical manufacturing, including exposure to aggressive chemicals, cleaning agents, and sterilization procedures. Modern pressure sensors incorporate sophisticated diagnostic capabilities that can detect potential sensor failures and provide early warning of developing problems.

Gas detection systems provide essential protection against the release of toxic or flammable gases that could pose serious hazards to facility personnel. These systems must be capable of detecting very low concentrations of hazardous gases while avoiding false alarms that could disrupt manufacturing operations. Advanced gas detection technologies include electrochemical sensors, infrared analyzers, and photoionization detectors, each offering specific advantages for different applications.

Environmental monitoring systems provide comprehensive surveillance of air quality, particulate levels, and other environmental conditions that could indicate containment failures or other safety issues. These systems often integrate with facility ventilation systems to provide automatic response to detected problems, including isolation of contaminated areas and activation of emergency ventilation procedures.

Emergency detection and alarm systems provide rapid notification of safety emergencies and coordinate appropriate response actions. These systems must be designed to operate reliably under emergency conditions, including power failures, communication system disruptions, and physical damage to facility infrastructure.

Administrative Controls and Procedures

While engineering controls provide the primary protection against pressure-related hazards, administrative controls and procedures play essential supporting roles in maintaining safe operations. These systems ensure that personnel are properly trained, equipment is properly maintained, and emergency procedures are effectively implemented when needed.

Operating procedures provide detailed instructions for safe operation of pressure systems under both normal and emergency conditions. These procedures must be comprehensive, clearly written, and regularly updated to reflect changes in equipment, processes, or regulatory requirements. Effective procedures also include specific instructions for recognizing and responding to abnormal conditions that could indicate developing safety problems.

Training programs ensure that all personnel who work with or around pressure systems understand the hazards involved and know how to operate safely. These programs must address both routine operations and emergency response procedures, providing hands-on training with actual equipment whenever possible. Regular refresher training ensures that personnel maintain current knowledge and skills even as equipment and procedures evolve.

Maintenance programs ensure that pressure protection systems continue to operate reliably throughout their service life. These programs must address both routine preventive maintenance and comprehensive inspection and testing procedures that verify system performance. Predictive maintenance technologies, including vibration analysis, thermal imaging, and oil analysis, can help identify potential problems before they result in equipment failures.

Management of change procedures ensure that modifications to pressure systems are properly evaluated for safety implications before implementation. These procedures must address both permanent modifications and temporary changes that might be implemented during maintenance or troubleshooting activities.

Emergency Response and Crisis Management

Comprehensive emergency response capabilities provide the final layer of protection against pressure-related incidents, ensuring that appropriate response actions are implemented quickly and effectively when prevention and protection systems are insufficient to prevent an incident.

Emergency shutdown systems provide rapid, automated shutdown of process equipment when hazardous conditions are detected. These systems must be designed to achieve safe shutdown conditions quickly while avoiding additional hazards that could result from rapid process changes. Advanced shutdown systems can prioritize shutdown sequences to minimize process disruption while ensuring personnel safety.

Evacuation procedures ensure that personnel can quickly and safely leave hazardous areas when necessary. These procedures must account for the specific layout and hazards of pharmaceutical facilities, including potential exposure to toxic chemicals, limited visibility due to vapor releases, and the need to secure hazardous materials before evacuation.

Emergency communication systems provide reliable communication capabilities during emergency situations, enabling coordination of response activities and notification of external emergency responders when necessary. These systems must operate reliably even when normal communication systems are disrupted by power failures or physical damage.

External emergency response coordination ensures that facility emergency procedures integrate effectively with community emergency response capabilities, including fire departments, hazardous materials teams, and emergency medical services.

Future Developments and Emerging Technologies

The future of pressure protection in pharmaceutical manufacturing promises continued advancement in both technology and methodology, driven by increasing regulatory expectations, advancing technology capabilities, and growing understanding of risk management principles.

Advanced sensor technologies offer new possibilities for more comprehensive and reliable monitoring of pressure conditions and related safety parameters. These technologies include wireless sensor networks that can provide monitoring in areas where traditional wired sensors are impractical, advanced materials that enable sensors to operate in more challenging environments, and artificial intelligence applications that can identify subtle patterns indicating developing problems.

Predictive safety systems represent an emerging approach that uses advanced data analysis to predict potential safety problems before they occur. These systems analyze patterns in process data, equipment performance, and environmental conditions to identify situations that have historically preceded safety incidents, enabling proactive interventions that prevent problems rather than simply responding after they occur.

Integration of safety systems with overall facility management systems promises more comprehensive and coordinated approaches to safety management. These integrated systems can consider complex interactions between different safety systems, optimize resource allocation for maximum safety benefit, and provide more comprehensive documentation of safety performance.

The pharmaceutical industry's commitment to pressure protection and safety continues to evolve as new technologies become available and understanding of safety risks continues to advance. The integration of advanced technologies with established safety principles promises to deliver ever more effective protection for pharmaceutical manufacturing operations, ensuring that these critical facilities can continue to produce life-saving medicines while maintaining the highest standards of safety for personnel and the community.

INDIA'S EXPORT OF BULK DRUGS & INTERMEDIATES
APRIL TO AUGUST

Values in US$

HS Code	Product Description	2024-25	2025-26
17023010	Glucose liquid	22.962375	22.846378
17023020	Glucose solid	4.701112	3.018387
17023031	Dextrose,solid	6.849748	8.471678
17023039	Dextrose other than solid	0.207773	0.171122
17024039	Dextrose other than solid	0.078243	0.046273
29051410	Ethambutol, ethambutol hcl	3.049238	2.030866
29051420	Salbutamol sulphate	4.860327	4.368723
29054300	Mannitol	2.212752	2.682174
29054400	D-glucitol (sorbitol)	25.219801	27.615066
29071930	Thymol	3.783882	2.756194
29072200	Hydroquinone	3.828502	5.145919
29095010	Guaiacol	0.816846	0.972853
29124920	Heliotropin (piperonyl aldehyde)	0.000001	0
29124940	3,4,5-trimethoxy-benzaldehyde	0.839754	0.942874
29154010	Monochloroacetic acide their salts and esters	5.204525	5.612099
29163120	Benzyl Benzoate	2.054031	1.580007
29163150	Benzocaine (ethylpara-amino benzoate)	1.055039	1.447568
29163400	Phenyl acetic acid	0.480179	0.64544
29171940	Ferrous fumerate	3.123545	3.285928
29171970	Ethoxy methylene malonate, diethyl malonate	0.001213	0.163796
29181120	Calcium lactate	0.071891	0.05081
29181320	Metroprolol tartrate	4.019311	4.059522
29181510	Potassium citrate	1.464046	1.247947
29181520	Sodium citrate	4.194222	5.629691
29181550	Ferric ammonium citrate	0.261237	0.453192
29181610	Calcium gluconate	2.914015	2.296947
29181620	Ferrous gluconate	0.445858	0.257579
29182110	Salicylic acid	1.071859	1.401551
29182120	Sodium salicylate	1.30987	0.852178
29182200	0-acetylsalicylic acid its salts and estrs	0.615862	0.649988
29182310	Methyl salicylate	3.383324	3.594329
29182320	Amino salicylate	0.245149	0.222091
29183030	Nalidixic acid	0.64284	0.434264
29199010	Glycerophosphoric acid	0.017401	0.000036
29199030	Iron glycerophosphate	0.016032	0.005595
29214250	Herbicide	0	6.106289
29214600	amfetamine INN and its related apis	10.398028	33.699489

29215110	o phenylanediamine	0.374585	0.581709
29215120	M-phenylenediamine (m-di aminobenzene)	1.886543	13.297974
29215130	P-phenylenediamine	5.350777	3.464445
29215170	Para amini acetanalide	0.040453	0.219379
29223100	Amfepra none(inn), methdone & mormethadonesalts	0.111287	0.412945
29224100	Lysine and its esters salts thereof	0.716015	1.212709
29224210	Glutamic acid	0.059205	0.116364
29224220	Monosodium glutamate (aginamoto)	0.312474	0.252336
29224400	Tilidine (INN) and its salts	0.029459	0.03751
29224910	Amino acetic acid (glycine)	8.356268	6.916751
29224920	N-methyl taurine	0.015664	0.033833
29225011	Para-amino-salicylic acid	0.001363	0.003003
29225013	Procaine hydrochloride	0.033093	0.047483
29225015	L-tyrosine(p-hydroxyphenylamine)	0.008036	0.001167
29225021	Frusemide	7.71842	7.642512
29225024	D0mperid0ne	3.843318	3.202109
29231000	Choline and its salts	3.900496	3.32135
29241100	Meprobamate (inn)	2.369249	0.354762
29242910	Acetanilide	0.122692	0.064489
29242960	Pyrazinamide(pyrazine carboxamide)	2.120036	1.598343
29242970	Pretilachlor	0.023524	6.468537
29242980	Paracetamol	37.307978	33.940119
29262000	1-Cyanoguanidine (dicyandiamide)	0.001603	0.005225
29263000	Fenproporex (inn) & its salts	0.037196	0.00022
29264000	Alpha-phenylacetoacetonitrile	0	0.003252
29280010	Isoniazid	0.448321	0.506296
29309014	Industrial chemical	0	2.442627
29309040	L-cystine (alpha-amino beta-thiopropionic acid)	0.993585	0
29322010	Coumarin,mthylcoumrn & ehylcoumrn-lactones	4.271397	4.853606
29331100	Phenazone (antipyrin) and its derivatives	4.524721	4.148878
29331910	3-carboxy (para sulpho-phenyl)-5-pyrazolone	0.912463	0.959284
29331920	1 (2,5- dichloro-4-sulpho phenyl)-3-methyl 5 Pyrazolone	0.389109	0.393755
29331930	3-methyl-1(4-sulpho-O-toluyl-5-pyrazolone)	0.501884	0.078346
29331940	Phenylmethylpyrazolone	0.011447	0.019642
29331950	1-phenyl-5-pyrazolone-3-carboxylic acid	0.018941	0.000075

29331960	1-(m-sulphophenyl)-3-pyrazolone	0	0.059412
29332910	Tinidazole	1.49451	1.572798
29332920	Metronidazole metronidiazole benzoate	6.057439	7.57124
29332930	Mebendazole	2.264592	3.234689
29332940	Dimetridazole	3.992966	1.649392
29334100	Levorphanol (inn) and its salts	0.421219	0
29334110	Levorphanol (inn) and its salts	0	0.65701
29334190	Other Containing structure of quinoline or iso quinoline ring halogenated or non halogentated and not further fused	0	2.734055
29335200	Malonylurea (barbituric acid) & its sals	0.100971	0.392994
29335300	Allobarbital and othr barbital compnds andits salts	1.988227	1.281564
29335400	Other derivatives of malonylurea (barbituric acid), salts thereof	0.756749	0.405792
29335910	Aminophylline(cordophylin)	0.304168	0.145693
29335920	Trimethoprim	5.264518	5.952304
29335930	Diethyl carbanazine citrate	0.145324	0.042649
29335940	1-Amino-4-Methyl piperazine	1.620468	2.337648
29335950	Bispiribac Sodium(Herbicide)	0	3.73915
29339100	Alpra zolam, camazepam & other cmpnds of zepam, salts thereof	7.958521	8.88294
29339200	Azinphos-methyl (ISO)	0.016546	0.03365
29349100	Aminorex, brotizolam and other like cmpnds, salts thereof	3.66791	8.28746
29349200	Fentanyl	0.061384	0.543214
29349910	Chloro Thiophene-2-Carboxylic Acid	0.043808	0.037536
29349990	Other Hetrocyclic compounds	212.734426	303.959135
29351000	N-Methylperfluorooctane sulphonamide	0.045258	0.268633
29352000	N-Ethylperfluorooctane sulphonamide	0	0.040771
29355090	Other Perfluro Octane Suphonomides	0.647782	0.748508
29359011	Sulphamethoxazole	13.823662	13.469721
29359012	Sulphafurazole	0.005861	0
29359013	Sulphadiazine	2.089022	2.488413
29359014	Sulphadimidine	0.035875	0.018206
29359015	Sulphacetamide	0.005386	0
29359022	Sulphamethiazole	0	2.836267
29359040	Pyrazosuluron ethyl(Pesticide)	0	0.083258

29362100	Vitamins a and their derivatives	11.249806	9.464351
29362210	Vitamin b1i(thiamine, aneurine) & its salt	3.889725	4.008417
29362290	Other vitamin b1i and its drivatives	8.867694	5.401425
29362310	Vitamin b2 (riboflavin, lactoplavin) and its salts	4.974039	4.879328
29362390	Other vitamin b2 and its derivatives	0.131258	0.001289
29362400	D-or dl-pantothenic acid (vitamin b3 or vitamin b5) and its derivatives	0.302767	0.151899
29362500	Vitamin b6 & its drvts	0.064818	0.472398
29362610	Vitamin b12 (cynocobalamin)	0.347597	0.639089
29362690	Other vitamin b12 and its derivatives	1.450486	6.002971
29362700	Vitamin c (ascorbic acid) & its drvtvs	4.49668	5.153276
29362800	Vitamin e and its derivatives	8.276818	9.971135
29362910	Folic acid (vitamin b9)	2.31258	2.657394
29362920	Nctnc acid & nctnmd(niacinamide/niacine	35.665356	32.608375
29362930	Vitamin k (menaphthonum b.p.)	0.862111	5.37541
29362940	Vitamin d	6.393269	12.331251
29362950	Vitamin h (bi0lin)	0.310606	0.129389
29362990	Other vitamins and thr drvtvs	7.189298	7.530946
29369000	Other, incl. natural concentrts	15.02169	23.287639
29371100	Somatotropin, its drvtvs& strctl analogves	0.112682	0.066829
29371200	Insulin and its salts	17.531418	15.714625
29371900	Other polypeptide hormones thr dtvtvs & strctl anlges	10.737632	14.636784
29372100	Cortisone,hydrocortisone,prednisone (dehy-drocortisone)and frednisolone and prdnsln(dehydrohydrocortisone)	5.206842	5.039953
29372200	Halgntd drvtvs of corti costeroidal	14.174856	12.22161
29372300	Oestrogens and progestogens	9.642658	7.764964
29372900	Othr steroidal hormons thr drvtvs and strctl anlges	47.438589	45.300238
29375000	Prostaglandins, tiromboxames& leukotrienesthr drvtvs & strclt anlges	0.551481	0.365506

29379019	Other Catecholamine hormones, their derivatives and structural analogues	0.799061	0.229696
29379020	Amino acide Derivatives	8.220288	7.317202
29379090	Other Amino acide Derivatives	12.138891	9.303229
29381000	Rutoside (rutin) and its derivatives	0.00171	0.000792
29389010	Digoxin	1.071105	0.396236
29389090	Other glycosides ntrl/rprdcd by synthsis &thr slts ethrs drvtvs	19.703012	30.065978
29391100	Concentrates of poppy straw cmpnds of morphin, codeine, codone, the baine, salts thereof	0.004646	0.13207
29392010	Quinine alkaloids	0.000024	0.000024
29392020	Quinine hydrochloride	0.915992	1.786954
29392030	Quinine sulphate	0.544305	0.198252
29392040	Chl0r0quine ph0sphate	0.582112	0.7202
29393000	Caffeine and its salts	21.564851	28.313982
29394100	Ephedrine & its salts	0.90489	1.291896
29394400	Norephedrine and its salts	0.387173	0.786203
29394900	Other ephedrives and thr salts	0.967055	0.769831
29395900	Other theophylline and aminophylline thr drvtvs, salts	15.535238	18.147988
29396900	Other alkaloids of rye ergot & drvtvs	1.271729	0.598814
29397900	Other of Vegitable origin	48.360263	70.904275
29398000	Non Vegetable Alkaloids	6.87245	5.052877
29411010	Penicillins and its salts	0.014687	0.070831
29411020	Ampicilline & its salts	12.028471	10.23313
29411030	Amoxycilline & its salts	72.750533	63.652151
29411040	Cloxacilline & its salts	9.797871	8.708775
29411090	Other penicillins & thr drvtvs wth a pentcillianic acid strctr slts thereof	30.023564	36.694409
29412010	Streptomycins	0.006243	0.032214
29412090	Other streptomycine & drvtvs, salts	0.008287	0.202066
29413010	Doxycylime & its salts	0.373202	0.404699
29413020	Tetracycline/oxytetra - cycline & hr salts	1.303039	0.378263
29413090	Other tetracyclines & thr drvtvs slts	0.035786	0.061469
29414000	Chloramphenicol & its drvtvs slts thereof	1.130353	0.967827
29415000	Erthromycin & its drvtvs slts thereof	43.845201	39.611505
29419011	Rifampicin	4.444	6.715837
29419014	1-Amino-4-Methyl piperazine (Rifaint)	0	0.000007

29419019	Other rifampicin and its salts	4.451792	2.205279
29419020	Cephalexin & its salts	5.518811	2.518307
29419030	Ciprofloxacine & its salts	8.116748	8.68782
29419040	Gentamycin & its salts	0.027256	0.001233
29419050	Neomycin	0.001686	0.060635
29419060	Norfloxacin & its salts	0.746788	1.081442
29419070	Other antibiotics	0	0.002446
29419090	Other antibiotics	228.002578	168.686599
29420011	Cefadroxil	8.32082	11.464383
29420012	Ibuprofane	31.51866	28.362122
29420013	Nifedipine	0.695071	1.386915
29420014	Ranitidine	3.122737	2.91901
29420016	Timolo maleate, terbutoline sulphate, imipramine HCl, amitryptyline, Atenolol,Propanolol	0.000055	0.022074
29420021	Timolol maleate	2.557584	2.19663
29420022	Terbutoline sulphate	0.41084	0.55123
29420024	Imipramine hcl	0.18673	0.288801
29420025	Amitryptyline hcl	2.379861	1.876419
29420027	Atenolol, propronalol	4.45815	4.965722
29420031	Diloxanide furoate	1.222672	1.068948
29420033	Oxyclozanide	2.466187	3.422423
29420034	Famotidine	5.279024	5.725325
29420090	Other diloxanide furoate, cimetidine, famotidine nes	426.410669	442.308048
29329300	3 -Carboxy(Para sulpho- phenyl)-5-Pyrazololne	0.081024	0
29329600	Carbofuran	0.000946	0
29349930	Pramoxine	0.000171	6.328042
29373100	Epinethrine	0	0.000001
29394500	Levo Methaphatamine	0	0.000096
29396110	Ergometrine	0.00039	0
29411050	6 - apa	0.000001	0
29419012	3 Formyl Rifa S V(Rifaint)	0	0.00001
29419013	Rifa S or Rifa S Sodium (Rifaint)	0.201417	0
29420032	Cimetidine	0	0.032479
		1743.811225	1896.032489

India's imports of Bulk drugs April-August

values in US$

HS code	Description	2024-25	2025-26
17023010	Glucose liquid	0.033768	0.080885
17023020	Glucose solid	0.411081	0.46451
17023031	Dextrose,solid	0.222717	0.35366
17023039	Dextrose other than solid	0.339731	0.462356
17024039	Dextrose other than solid	0.000082	0.131424
29051410	Ethambutol, ethambutol hcl	1.758919	2.05338
29051420	Salbutamol sulphate	0.130166	0.175121
29054300	Mannitol	19.755818	25.574443
29054400	D-glucitol (sorbitol)	4.441339	4.497249
29071930	Thymol	0.045104	0.049043
29072200	Hydroquinone	14.55807	14.873847
29095010	Guaiacol	0.290919	1.097057
29124940	3,4,5-trimethoxy-benzaldehyde	0.1765	0.290098
29154010	Monochloroacetic acide their salts and esters	1.23503	0.344957
29163120	Benzyl Benzoate	0.156369	0.49801
29163150	Benzocaine (ethylpara-amino benzoate)	0.000679	0.04576
29163400	Phenyl acetic acid	1.723756	0.000024
29171940	Ferrous fumerate	0.026678	0.040086
29171970	Ethoxy methylene malonate, diethyl malonate	8.729316	6.776878
29181120	Calcium lactate	0.191985	0.162661
29181320	Metroprolol tartrate	0.214307	1.105058
29181510	Potassium citrate	0.908654	0.590902
29181520	Sodium citrate	0.936462	1.789858
29181610	Calcium gluconate	3.915952	3.455645
29181620	Ferrous gluconate	0	0.015049
29182110	Salicylic acid	12.276331	8.887865
29182120	Sodium salicylate	0.032369	0.061602
29182200	0-acetylsalicylic acid its salts and estrs	0.13505	0.370366
29182310	Methyl salicylate	0.540946	0.430718
29183030	Nalidixic acid	0.559935	0.242776
29199010	Glycerophosphoric acid	0.001666	0
29214600	amfetamine INN and its related apis	0.234376	0.083553
29215110	o phenylanediamine	7.815957	6.152491
29215120	M-phenylenediamine (m-di aminobenzene)	1.618954	1.627279
29215130	P-phenylenediamine	2.630427	2.038693
29224100	Lysine and its esters salts thereof	57.649742	48.062638
29224210	Glutamic acid	0.428972	0.327375
29224220	Monosodium glutamate (aginamoto)	27.464746	26.117236
29224910	Amino acetic acid (glycine)	10.212674	7.527388

29224920	N-methyl taurine	0.303206	1.891747
29225011	Para-amino-salicylic acid	0.117905	0.010874
29225013	Procaine hydrochloride	0	0.014258
29225015	L-tyrosine(p-hydroxyphenylamine)	0.802325	1.590693
29225021	Frusemide	0.048506	0.24726
29231000	Choline and its salts	1.104923	0.651034
29335200	Malonylurea (barbituric acid) & its sals	2.139251	2.82517
29335300	Allobarbital and othr barbital compnds andits salts	0.003732	0.037314
29335400	Other derivatives of malonylurea (barbituric acid), salts thereof	0.003289	0.425378
29335910	Aminophylline(cordophylin)	0.366658	0.107153
29335920	Trimethoprim	0.069114	0.19876
29335940	1-Amino-4-Methyl piperazine	0.01202	0.018529
29335950	Bispiribac Sodium(Herbicide)	0.000183	0.010376
29339100	Alpra zolam, camazepam & other cmpnds of zepam, salts thereof	1.137708	0.976505
29339200	Azinphos-methyl (ISO)	0	0.000367
29349100	Aminorex, brotizolam and other like cmpnds, salts thereof	0.022569	0
29349200	Fentanyl	0.358606	0.182632
29349910	Chloro Thiophene-2-Carboxylic Acid	0.077295	0.3907
29349990	Other Hetrocyclic compounds	314.176464	269.276788
29351000	N-Methylperfluorooctane sulphonamide	0.022431	0
29355090	Other Perfluro Octane Suphonomides	0.00829	0.767878
29359011	Sulphamethoxazole	0.024574	0.018051
29359013	Sulphadiazine	0.250145	0.435598
29359014	Sulphadimidine	0.835017	0.978768
29359040	Pyrazosuluron ethyl(Pesticide)	0	0.403899
29362100	Vitamins a and their derivatives	5.809869	6.080373
29362210	Vitamin b1i(thiamine, aneurine) & its salt	4.986209	11.45101
29362290	Other vitamin b1i and its drivatives	1.524191	1.322707
29362310	Vitamin b2 (riboflavin, lactoplavin) and its salts	5.799306	3.51838
29362390	Other vitamin b2 and its derivatives	2.761242	1.750459
29362400	D-or dl-pantothenic acid (vitamin b3 or vitamin b5) and its derivatives	3.930695	3.891655
29362500	Vitamin b6 & its drvts	6.070348	5.887072
29362610	Vitamin b12 (cynocobalamin)	11.489483	14.956999
29362690	Other vitamin b12 and its derivatives	0.667428	1.59897
29362700	Vitamin c (ascorbic acid) & its drvtvs	5.786256	12.771869
29362800	Vitamin e and its derivatives	18.989525	26.678883
29362910	Folic acid (vitamin b9)	1.404855	2.799268
29362920	Nctnc acid & nctnmd(niacinamide/niacine	0.640059	0.327406

29362930	Vitamin k (menaphthonum b.p.)	0.891789	0.860359
29362940	Vitamin d	5.634962	6.939311
29362950	Vitamin h (bi0lin)	0.590435	0.687328
29362990	Other vitamins and thr drvtvs	8.332425	4.865121
29369000	Other, incl. natural concentrts	0.414129	1.066946
29371100	Somatotropin, its drvtvs& strctl analogves	0.000298	0.000935
29371200	Insulin and its salts	15.971148	23.448275
29371900	Other polypeptide hormones thr dtvtvs & strctl anlges	18.277222	32.207689
29372100	Cortisone,hydrocortisone,prednisone (dehy-drocortisone)and frednisolone and prdnsln(dehydrohydrocortisone)	20.627438	16.031975
29372200	Halgntd drvtvs of corti costeroidal	10.017112	11.787718
29372300	Oestrogens and progestogens	25.702272	25.608875
29372900	Othr steroidal hormons thr drvtvs and strctl anlges	45.085261	42.832843
29375000	Prostaglandins, tiromboxames& leukotrienesthr drvtvs & strclt anlges	3.02196	0.892266
29379019	Other Catecholamine hormones, their derivatives and structural analogues	2.465043	1.404712
29379020	Amino acide Derivatives	5.51928	3.626162
29379090	Other Amino acide Derivatives	24.885429	27.518248
29381000	Rutoside (rutin) and its derivatives	2.487756	2.445455
29389010	Digoxin	0.02258	0.000552
29389090	Other glycosides ntrl/rprdcd by synthsis &thr slts ethrs drvtvs	33.104534	26.85394
29391100	Concentrates of poppy straw cmpnds of morphin, codeine, codone, the baine, salts thereof	5.531143	1.471665
29392010	Quinine alkaloids	0.317311	0.385908
29392020	Quinine hydrochloride	0.003853	0
29392030	Quinine sulphate	0.128186	0.198337
29393000	Caffeine and its salts	8.746924	16.131157
29394100	Ephedrine & its salts	0.006373	0.088684
29394400	Norephedrine and its salts	0.000796	0.014857
29394900	Other ephedrives and thr salts	0.387229	0.393021
29395900	Other theophylline and aminophylline thr drvtvs, salts	1.216179	2.73758
29396900	Other alkaloids of rye ergot & drvtvs	1.294118	0.892844
29397900	Other of Vegitable origin	1.409902	4.701001
29398000	Non Vegetable Alkaloids	5.754226	1.271822
29411010	Penicillins and its salts	83.118244	41.779171
29411020	Ampicilline & its salts	0.279795	0.019882
29411030	Amoxycilline & its salts	20.726674	15.252758
29411040	Cloxacilline & its salts	0.401664	0.394143

29411090	Other penicillins & thr drvtvs wth a pentcillianic acid strctr slts thereof	37.72076	35.678703
29412010	Streptomycins	1.876215	2.189982
29412090	Other streptomycine & drvtvs, salts	0.930814	0.825965
29413010	Doxycylime & its salts	8.026357	12.19779
29413020	Tetracycline/oxytetra - cycline & hr salts	4.626758	4.989834
29413090	Other tetracyclines & thr drvtvs slts	9.594638	10.238442
29414000	Chloramphenicol & its drvtvs slts thereof	1.027222	0.170464
29415000	Erthromycin & its drvtvs slts thereof	69.874107	79.973382
29419011	Rifampicin	14.657123	30.143251
29419014	1-Amino-4-Methyl piperazine (Rifaint)	0.07585	0
29419019	Other rifampicin and its salts	23.502927	26.332841
29419020	Cephalexin & its salts	14.239711	11.900514
29419030	Ciprofloxacine & its salts	4.572451	2.206419
29419040	Gentamycin & its salts	4.010657	2.4351
29419050	Neomycin	1.079878	1.421924
29419060	Norfloxacin & its salts	5.362967	2.65687
29419090	Other antibiotics	318.092764	325.326807
29420011	Cefadroxil	0.972959	0.063055
29420012	Ibuprofane	1.605617	3.80069
29420013	Nifedipine	0.009844	0
29420014	Ranitidine	0	0.188863
29420016	Timolo maleate, terbutoline sulphate, imipramine HCl, amitryptyline, Atenolol,Propanolol	11.930966	5.517371
29420021	Timolol maleate	0.154836	0.136409
29420022	Terbutoline sulphate	0	0.022772
29420025	Amitryptyline hcl	0.028991	0
29420027	Atenolol, propronalol	1.017378	0.034332
29420034	Famotidine	0.182134	0.177435
29420090	Other diloxanide furoate, cimetidine, famotidine nes	131.104666	138.726179
90189097	Surgical appliances	2.08446	0.177739
29335500	Loprazolam, mecloqualone, methaqualone , ziperol, salts thereof	0.000314	0
29349930	Pramoxine	0.00202	0.001565
29359023	Sulphamoxole	0.000288	0
29379011	Epinethrine	0.001162	0.003006
29389020	Digitalis glycosides	0.085562	0
29394300	Cathine(INN) & its salts	0	0.002111
29394500	Levo Methaphatamine	0.000953	0
29396190	Other ergometrine salts	0.095802	0.025447
29396210	Ergotamine tartarate	0.363854	0
29396290	Other ergotamine salts	0.035508	0

29397200	Cocaine, ecgonine, levometamfetamin, metamfetamine (INN), metamfetamine racemate; salts, esters and other derivatives thereof	0.090422	0
29411050	6 - apa	177.73863	154.656723
29419013	Rifa S or Rifa S Sodium (Rifaint)	4.836419	17.020578
29420015	Danes salt of D(-) phenyl glycine	8.291405	7.410197
29420023	D(-) phenyl glycin chloride HCL (DPGCH)	0	0.036711
29420026	Cysteanune hcl	1.199637	1.551294
29420032	Cimetidine	0.262896	0.18623
		1787.290836	1734.591259

CPHI India | PMEC India

informa markets

25th November - 27th November, 2025 India Expo Center (IEML), Greater Noida, Delhi NCR

Some events Inform.
Some events Inspire.
This one Transforms

Get ready to enter the future of Pharma
at #CPHIAndPMECIndia2025

Important Note:

The organizers of Global ChemiShow offered 30 stalls (fully furnished 9 sq. meter stalls) on Complimentary basis. 12 of our members have already taken the Stalls. Members who are interested to avail these FREE stalls, please write to ed@bdmai.org ; info@bdmai.org; Stalls will be allotted on first-come-first-serve basis.